HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Gain Therapeutics (NASDAQ:GANX) but lowered the price target from $9 to $8.
July 02, 2024 | 10:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Gain Therapeutics but lowered the price target from $9 to $8.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more conservative outlook on its potential upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100